2024
What is the safety of COVID-19 vaccines in immunocompromised patients? Results from the European “Covid Vaccine Monitor” active surveillance study
Bellitto C, Luxi N, Ciccimarra F, L’Abbate L, Raethke M, van Hunsel F, Lieber T, Mulder E, Riefolo F, Villalobos F, Thurin N H, Batel Marques F, Morton K, O’Shaughnessy F,Sonderlichová S, Farcas A, Janneke G-E, Sturkenboom M C & Trifirò G.
Drug Saf. 2024 Oct;47(10):1011-1023.
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study
Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T, Mulder E, L’Abbate L, Riefolo F, Batel Marques F, Furci F, Farcas A, Giele-Eshuis J, Morton K, Sonderlichová S, Thurin N H, Villalobos F, Riefolo F, Sturkenboom M C & Trifirò G.
Vaccines (Basel). 2024 Sep 17;12(9):1059.
Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Lessons Learnt From the MINERVA Project in Europe
Gini R, Pajouheshnia R, Gutierrez L, Swertz M A, Hyde E, Sturkenboom M, Arana A, Franzoni C, Ehrenstein V, Roberto G, Gil M, Maciá M A, Schäfer W, Haug U, Thurin N H, Lassalle R, Droz-Perroteau C, Zaccagnino S, Busto M P, Middelkoop B, Gembert K, Sanchez-Saez F, Rodriguez-Bernal C, Sanfélix-Gimeno G, Hurtado I, Barreiro-de Acosta M, Poblador-Plou B, Carmona-Pírez J, Gimeno-Miguel A, Prados-Torres A, Schultze A, Jansen E, Herings R, Kuiper J, Locatelli I, Jazbar J, Žerovnik S, Kos M, Smit S, Lind S, Metspalu A, Simou S, Hedenmalm K, Cochino A, Alcini P, Kurz X, Perez-Gutthann S.
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5884.
Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies (MINERVA): development and pilot of a metadata list and catalogue in Europe
Pajouheshnia R,Gini R, Gutierrez L, Swertz M A, Hyde E, Sturkenboom M, Arana A, Franzoni C, Ehrenstein V, Roberto G, Gil M, Maciá M A, Schäfer W, Haug U, Thurin N H, Lassalle R, Droz-Perroteau C, Zaccagnino S, Busto M P, Middelkoop B, Gembert K, Sanchez-Saez F, Rodriguez-Bernal C, Sanfélix-Gimeno G, Hurtado I, Barreiro-de Acosta M, Poblador-Plou B, Carmona-Pírez J, Gimeno-Miguel A, Prados-Torres A, Schultze A, Jansen E, Herings R, Kuiper J, Locatelli I, Jazbar J, Žerovnik S, Kos M, Smit S, Lind S, Metspalu A, Simou S, Hedenmalm K, Cochino A, Alcini P, Kurz X, Perez-Gutthann S.
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5871.
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data
Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Omar M I, Alshammari T, Areia C, Asiimwe A, Beyer K, Bjartell A, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai L Y H, Maresca G, Mottet N, Oja M, Prinsen P, Reich C, Remmers S, Roobol M J, Sakalis V, Seager S, Smith E J, Snijder R, Steinbeisser C, Thurin N H, Hijazy A, van Bochove K, Van den Bergh R C N, Van Hemelrijck M, Willemse P-P, Williams A E, Kermani N Z, Evans-Axelsson S, Briganti A, N’Dow J, on behalf of the PIONEER
Consortium.
Eur Urol. 2024 May;85(5):457-465.
COVID‑19 and pregnancy: A European study on pre‑ and post‑infection medication use
Hurley E, Geisler B P, Lupattelli A, Poblador‑Plou B, Lassalle R, Jové J, Bernard M-A, Sakr D, Sanfélix‑Gimeno G, Sánchez‑Saez F, Rodríguez‑Bernal C L, Sabaté M, Ballarín E, Aguilera C, Jordan S, Thayer D, Farr I, Ahmed S, Bartolini C, Limoncella G, Paoletti O, Gini R, Maglanoc L A, Dudukina E, Ehrenstein V, Alsina E, Vaz T A, Riera‑Arnau J, Sturkenboom M C J M, Nordeng H M E.
Eur J Clin Pharmacol. 2024 May;80(5):707-716.
Young-Onset Dementia Among Individuals With History of Preeclampsia
Olié V, Lailler G, Torres M J,Regnault N, Carcaillon-Bentata L, Blacher J.
JAMA Netw Open. 2024 May 1;7(5):e2412870.
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study
Raethke M, van Hunsel F, Luxi N, Lieber T, Bellitto C, Mulder E, Ciccimarra F, Riefolo F, Thurin N H, Roy D, Morton K, Villalobos F, Batel Marques F, Farcas A, Sonderlichová S, Belitser S, Klungel O, Trifirò G, Sturkenboom M C.
Vaccine. 2024 Apr 2;42(9):2357-2369.
Analgesic switching in chronic users of dextropropoxyphene in France
Daveluy A, Bryan MC, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Floccia M, Haramburu F, Lapeyre-Mestre M, Micallef J, Salvo F.
Fundam Clin Pharmacol. 2024 Apr;38(2):389-397.
Design and validation of algorithms to identify Venous Thromboembolism in the French National Healthcare Database
Thurin N H, Grelaud A, Grolleau A, Bernard M-A, Bignon E, Blin P, Lassalle R, Droz-Perroteau C.
Pharmacoepidemiol Drug Saf. 2024 Apr;33(4):e5781.
Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study
Ciccimarra F, Luxi N, Bellitto C, L’Abbate L, Raethke M, van Hunsel F, Lieber T, Mulder E, Riefolo F, Dureau-Pournin C, Farcas A,
Batel Marques F, Morton K, Roy D, Sonderlichová S, Thurin N H, Villalobos F, Sturkenboom M C, Trifirò G.
Vaccines (Basel). 2024 Feb 26;12(3):241.
Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database
Blin P, Joubert M, Jourdain P, Zaoui P, Guiard E, Sakr D, Dureau-Pournin C, Bernard M-A, Lassalle R, Thomas-Delecourt F, Bineau S, Moore N, Droz-Perroteau C.
Cardiovasc Diabetol. 2024 Jan 9;23(1):22.
2023
Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case–control study within the French nationwide claims database
Bosco-Lévy P, Boutmy E, Guiard E, Foch C, Lassalle R, Favary C, Sabido M, Blin P.
Pharmacoepidemiol Drug Saf. 2023 Dec;32(12):1421-1430.
Drug utilization analysis of osteoporosis medications in seven European electronic health databases
Tan E H, Robinson D E, Jödicke A M, Mosseveld M, Bødkergaard K,
Reyes C, Moayyeri A, Voss A, Marconi E, Lapi F, Reinold J, Verhamme K M C, Pedersen L, Braitmaier M, de Wilde M, Ruiz M F, Aragón M, Bosco‑Levy P, Lassalle R, Prieto‑Alhambra D, Sanchez‑Santos M T.
Osteoporos Int. 2023 Oct;34(10):1771-1781.
Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer
Gouverneur A, Favary C, Jové J, Rouyer M, Bignon E, Salvo F, Tchalla A, Paillaud E, Aparicio T, Noize P.
Target Oncol. 2023 Sep;18(5):717-726.
Real-World Effectiveness of Osteoporosis Medications in France: A Nationwide Cohort Study
Bosco-Lévy P, Briot K, Mehsen-Cetre N, O'Kelly J, Désaméricq G, Abouelfath A, Lassalle R, Grelaud A, Grolleau A, Blin P and Droz-Perroteau C.
JBMR Plus. 2023 Jul 18;7(9):e10789.
Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality
Sing C-W, Lin T-C, Bartholomew S, Bell J S, Bennett C, Beyene K, Bosco-Levy P, Bradbury B D, Chan A H Y, Chandran M, Cooper C, de Ridder M, Doyon Y C, Droz-Perroteau C, Ganesan G, Hartikainen S, Ilomaki J, Jeong H E, Kiel D P, Kubota K, Chia-Cheng Lai E, Lange J L, Lewiecki E M, Lin J, Liu J, Maskell J, Mendes de Abreu M, O'Kelly J, Ooba N, Pedersen A B, Prats-Uribe A, Prieto-Alhambra D, Xiwen Qin S, Shin J-Y, Sørensen H T, Tan K B, Thomas T, Tolppanen A-M, Verhamme K, Wang G H-M, Watcharathanakij S, Wood J S, Cheung C-L, Ck Wong I.
J Bone Miner Res. 2023 Aug;38(8):1064-1075.
Safety of COVID‑19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials
Ahmadizar F, Luxi N, Raethke M, Schmikli S, Riefolo F, Saraswati P W, Bucsa C, Osman A, Liddiard M, Batel Maques F, Petrelli G, Sonderlichová S, Thurin N H, Villalobos F, Trifirò G, Sturkenboom M.
Drug Saf. 2023 Jun;46(6):575-585.
Cohort Event Monitoring of Adverse Reactions to COVID‑19 Vaccines in Seven European Countries: Pooled Results on First Dose
Raethke M, van Hunsel F, Thurin NH, Dureau‑Pournin C, Mentzer D, Kovačić B, Mirošević Skvrce N, De Clercq E, Sabbe M, Trifirò G, Luxi N, Giovanazzi A,Shakir S, Klungel OH, Schmikli S, Sturkenboom M.
Drug Saf. 2023 Apr;46(4):391-404.
Strong instrumental variables biased propensity scores in comparative effectiveness research: a case study in oncology
Thurin NH, Jové J, Lassalle R, Rouyer M, Lamarque S, Bosco-Levy P, Segalas C, Schneeweiss S, Blin P, Droz-Perroteau C.
J Clin Epidemiol. 2023 Mar;155:31-38.
Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases
Salinas C-A, Louder A, Polinski J, Zhang T-C, Bower H, Phillips S, Song Y, Rashidi E, Bosan R, Chang H-C, Foster N, Gershenson B, Yamanaka H, Kishimoto M, Tanaka Y, Fischer P, Zhu B, Faries D, Mai X, Doherty B-T, Grelaud A, Thurin N-H, Askling J, Deberdt W. on behalf of the B023 Study Consortium
Rheumatol Ther. 2023 Feb;10(1):201-223.
High-dimensional propensity scores for empirical covariate selection in secondary database studies: planning, implementation, and reporting
Rassen J-A, Blin P, Kloss S, Neugebauer R-S, Platt R-W, Pottegård A, Schneeweiss S, Sengwee T.
Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):93-106.
Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location
Kasper S, Foch C, Esser R, Lamy F-X, Zhang A, Cheng A-L, Rouyer M, Brodowicz T, Zielinski C.
Eur J Cancer. 2023 Feb;180:85-88.
Clustering of prostate cancer healthcare pathways in the French National Healthcare database
Baulain R, Jové J, Sakr D, Gross-Goupil M, Rouyer M, Puel M, Blin P, Droz-Perroteau C, Lassalle R, Thurin NH.
Cancer Innov. 2023 Jan 17;2(1):52-64.
Background rates of 41 Adverse Events of Special Interest for COVID-19 vaccines in 10 European healthcare databases - An ACCESS cohort study
Willame C, Dodd C, Durán CE, Elbers RJHJ, Gini R, Bartolini C, Paoletti O, Wang L, Ehrenstein V, Kahlert J, Haug U, Schink T, Diez-Domingo J, Mira-Iglesias A, Carreras JJ, Vergara- Hernández C, Giaquinto C, Barbieri E, Stona L, Huerta C, Martín-Pérez M, García-Poza P, de Burgos
A, Martínez-González M, Bryant V, Villalobos F, Pallejà-Millán M, Aragón M, Carreras JJ, Souverein P, Thurin NH, Weibel D, Klungel OH, Sturkenboom MCJM
Vaccine. 2023 Jan 4;41(1):251-262.
Real-world data and evidence in health technology assessment: when are they complementary, substitutes, or the only sources of data compared to clinical trials?
de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Therapie. 2023 Jan-Feb;78(1):81-94.
2022
Towards an Interoperable Ecosystem of Research Cohort and Real-world Data Catalogues Enabling Multi-center Studies
Swertz M, van Enckevort E, Oliveira J-L, Fortier I, Bergeron J, Thurin N-H, Hyde E, Kellmann A, Pahoueshnja R, Sturkenboom M, Cunnington M, Nybo Andersen A-M, Marcon Y, Gonçalves G, Gini R.
Yearb Med Inform. 2022 Aug;31(1):262-272.
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Thurin NH, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rébillard X, Soulié M, de Pouvourville G, Capone C, Bazil M-L, Messaoudi F, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P.
Expert Rev Clin Pharmacol. 2022 Sep;15(9):1139-1145.
Incidence and risk of cancer among Multiple Sclerosis patients: a matched population-based cohort study
Bosco-Lévy P, Foch C, Grelaud A , Sabidó M, Lacueille C, Jové J, Boutmy E, Blin P.
Eur J Neurol. 2022 Apr;29(4):1091-1099.
doi: 10.1111/ene.15226.
Adverse drug reactions induced by cotrimoxazole: Still a lot of preventable harm.
Coppry M, Duret S, Berdaï D, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Rogues AM, Noize P.
Fundam Clin Pharmacol. 2022 Apr;36(2):421-426.
Comparative effectiveness of dimethyl fumarate in Multiple Sclerosis
Bosco-Lévy P, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef O, Lignot S, Diez P, Abouelfath A, Lassalle R, Blin P, Droz-Perroteau C.
Br J Clin Pharmacol. 2022 Mar;88(3):1268-1278.
From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding
Thurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, Paoletti O, Nordeng H, Wallach-Kildemoes H, Ehrenstein V, Dudukina E, MacDonald T, De Paoli G, Loane M, Damase-Michel C, Beau A-B, Droz-Perroteau C, Lassalle R, Bergman J, Swart K, Schink T, Cavero-Carbonell C, Barrachina-Bonet L, Gomez-Lumbreras A, Giner-Soriano M, Aragón M, Neville A-J, Puccini A, Pierini A, Ientile V, Trifirò G, Rissmann A, Leinonen M-K, Martikainen V, Jordan S, Thayer D, Scanlon I, Georgiou M-E, Cunnington M, Swertz M, Sturkenboom M, Gini R.
Clin Pharmacol Ther. 2022 Jan;111(1):321-331.
2021
Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database
Blin P,Darmon P, Henry P, Guiard E, Bernard M-A, Dureau-Pournin C, Maizi H, Thomas-Delecourt F, Lassalle R, Droz-Perroteau C, Moore N.
Cardiovasc Diabetol. 2021 Nov 25;20(1):229.
Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)
Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Grave B, Huerta C, Martin-Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjær M, Andersen M, De Bruin ML, Souverein P, Klungel OH, Gardarsdottir H, Ibáñez L.
Front Pharmacol. 2021 Nov 3;12:682890.
Nurses'internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study
Villa A, Molimard M, Sakr D, Lassalle R, Bignon E, Martinez B, Rouyer M, Mathoulin-Pelissier S, Baldi I, Verdun-Esquer C, Canal-Raffin M.
Int Arch Occup Environ Health. 2021 Nov;94(8):1839-1850.
Ambulatory drug changes in the elderly after hospital discharge: A cohort study
Rousselot N, Joseph JP, Noïze P, Berdaï D, Fourrier-Réglat A, Bosco-Levy P.
Therapie. 2021 Nov-Dec;76(6):587-595.
Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe
Fortuny J, von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C, Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S, Schink T, Rascher K, Rasouliyan L, Rothman KJ, Saigi-Morgui N, Schaller M, Smits E, Forstner M, Intravenous Iron Consortium; Bénichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L.
Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-1457.
Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database.
Blin P, Rouyer M, Guiard E, Zerbib F, Diquet B, Mégraud F, Tison F, Abouelfath A, Lassalle R, Droz-Perroteau C, Moore N.
Therapie. Sep-Oct 2021;76(5):435-440.
NSAIDs and COVID-19: A Systematic Review and Meta-analysis
Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C.
Drug Saf. 2021 Sep;44(9):929-938.
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis.
Aubin HJ, Dureau-Pournin C, Falissard B, Paille F, Rigaud A, Micon S, Pénichon M, Andersohn F, Truchi C, Blin P.
Alcohol Alcohol. 2021 Aug 30;56(5):545-555.
Global epidemiology of hip fractures; a study protocol using a common analytical platform among multiple countries
Sing CW, Lin TC, Bartholomew S, Bell JS, Bennett C, Beyene K, Bosco-Lévy P, Yan Chan AH, Chandran M, Cheung CL, Doyon CY, Droz-Perroteau C, Ganesan G, Hartikainen S, Ilomaki J, Jeong HE, Kiel DP, Kubota K, Chia-Cheng Lai E , Lange J, Lewiecki EM, Liu J, Man KCM, Mendes de Abreu M, Moore N, O'Kelly J, Ooba N, Pedersen AB, Prieto-Alhambra D, Shin JY, Sørensen HT, Tan KB, Tolppanen AM,Verhamme KMC, Wang GHM, Watcharathanakij S, Zhao H, Wong ICK.
BMJ Open. 2021 Jul 28;11(7):e047258.
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study
Seneschal J, Duplaine A, Maillard H, Passeron T, Andreu N, Lassalle R, Favary C, Droitcourt C, Taïeb A, Ezzedine K.
J Invest Dermatol. 2021 Jul;141(7):1728-1734.
Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data
Thurin NH, Bosco-Levy P, Blin P, Rouyer M, Jové J, Lamarque S, Lignot S, Lassalle R, Abouelfath A, Bignon E, Diez P, Gross-Goupil M, Soulié M, Roumiguié M, Le Moulec S, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef E, Moore N and Droz-Perroteau C.
BMC Med Res Methodol. 2021 May 1;21(1):95.
Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response
Astrugue C, Bénard A, Bosco-Levy P, Dulucq S, Rouyer M, Lassalle R, Hayes N, Mahon FX.
Value Health. 2021 May;24(5):683-690.
Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the Erebus cohort.
Rouyer M, Francois E, Sa Cunha A, Monnereau A, Bignon E, Jove J, Lassalle R, Droz-Perroteau C, Moore N, Noize P, Fourrier-Réglat A, Smith D.
Br J Clin Pharmacol. 2021 Mar;87(3):1120-1128.
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Souverein PC, van den Ham HA, Huerta C, Martín Merino E, Montero D, León‐Muñoz LM, Schmiedl S, Heeke A, Rottenkolber M, Andersen M, Aakjaer M, De Bruin ML, Klungel OH, Gardarsdottir H.
Br J Clin Pharmacol. 2021 Mar;87(3):988-1000.
Empirical assessment of case‐based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS).
Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz‐Perroteau C.
Pharmacoepidemiol Drug Saf. 2021 Mar;30(3):320-333.
Factors Associated With Serious Vehicular Accidents: A Cross-Sectional Study in Hospital Emergency Rooms.
Forest K, Valdenaire G, Lorendeau J-P, Sagaspe P, Contrand B, Durand-Teyssier C, Sakr D, Gil-Jardine C, Boutreux S, Lagarde E, Peyrouzet H, Lassalle R, Moore N, Philip P, Girodet P-O.
Br J Clin Pharmacol. 2021 Feb;87(2):612-621.
Ten-year Trend of Opioid and Nonopioid Analgesic Use in the French Adult Population.
Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Corand V, Victorri-Vigneau C, Batisse A, Le Boisselier R, Peyrière H, Frauger E, Lapeyre-Mestre M, Haramburu F.
Br J Clin Pharmacol. 2021 Feb;87(2):555-564.
Treatment resistant depression incidence and prevalence using the French nationwide claims database.
Bosco-Lévy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca P-M, Bernard M-A, Lassalle R, Moore N, Droz-Perroteau C.
Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):169-177.
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
Kasper S, Foch C, Messinger D, Esser R, Lamy FX, Rothe V, Chen W, Cheng AL, Rouyer M, Brodowicz T, Zielinski C.
Eur J Cancer. 2021 Feb;144:291-301.
Real-world outcomes after 36 months treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME).
Massin P, Creuzot-Garcher C, Kodjikian L, Girmens JF, Delcourt C, Fajnkuchen F, Glacet-Bernard A, Guillausseau PJ, Guthux F, Blin P, Grelaud A.
Ophthalmic Res. 2021;64(4):577-586.
The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study.
Gorwood P, Benichou J, Moore N, Álvarez Martínez E, Mertens J, Aguglia E, Figueira ML, Falkai P, Olivier V, Wattez M, Picarel-Blanchot F, de Bodinat C.
Hum Psychopharmacol. 2021 Jan;36(1):1-11.
2020
Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database.
Thurin NH, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, Roumiguié M, Le Moulec S, Capone C, Pierrès M, Lamarque S, Jové J, Bignon E, Droz-Perroteau C, Moore N, Blin P.
Cancer Epidemiol. 2020 Dec;69:101833.
Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
Gorwood P, Benichou J, Moore N, Wattez M, Secouard MC, Desobry X, Picarel-Blanchot F, de Bodinat C.
Clin Drug Investig. 2020 Nov;40(11):1009-1020.
Quality Of Life And Pain During Treatment Of Metastatic Castration-Resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice.
Joly F, Oudard S, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Rouyer M, Moore N.
Clin Genitourin Cancer. 2020 Oct;18(5):e510-e516.
Empirical assessment of case‐based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project.
Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz‐Perroteau C.
Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):993-1000.
No arguments for extra risk from ibuprofen in SARS-COV2 infection.
Moore N.
Therapie. Sep-Oct 2020;75(5):513-514.
Considerations for Pharmacoepidemiological Analyses in the SARS-CoV-2 Pandemic
Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O.
Pharmacoepidemiol Drug Saf. 2020 Aug;29(8):825-831.
Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS).
Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz-Perroteau C.
Pharmacoepidemiol Drug Saf. 2020 Aug;29(8):890-903.
Does Ibuprofen Worsen COVID-19?
Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C.
Drug Saf. 2020 Jul;43(7):611-614.
Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years.
Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE).
Br J Haematol. 2020 Jun;189(5):931-942.
Chloroquine for COVID-19 Infection.
Moore N.
Drug Saf. 2020 May;43(5):393-394.
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Moore N.
Drug Saf. 2020 Apr;43(4):301-318.
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
de Pouvourville G, Blin P, Karam P.
Eur J Health Econ. 2020 Mar;21(2):235-249.
Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.
Panes A, Pariente A, Bénard-Laribière A, Lassalle R, Dureau-Pournin C, Lorrain S, Tournier M, Fourrier-Réglat A.
Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):3-10.
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
Blin P, Dureau-Pournin C, Bénichou J, Cottin Y, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
Am J Cardiovasc Drugs. 2020 Feb;20(1):81-103.
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard MA, Lassalle R, Droz-Perroteau C, Dallongeville J, Moore N.
Europace. 2020 Feb 1;22(2):205-215.
Secondary prevention of acute coronary syndrome with antiplatelet agents in real life: A high-dimensional propensity score matched cohort study in the French National claims database.
Blin P, Dureau-Pournin C, Jové J, Lassalle R, Droz C, Moore N.
MethodsX. 2020 Jan 23.
Pharmacological treatment patterns in heart failure: a population-based cohort study.
Bosco-Lévy P, Favary C, Jové J, Lassalle R, Moore N, Droz-Perroteau C.
Eur J Clin Pharmacol. 2020 Jan;76(1):97-106.
2019
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N; FUJI Investigators.
Br J Cancer. 2019 Dec;121(12):1001-1008.
Pharmacovigilance - The next chapter.
Moore N, Berdaï D, Blin P, Droz C.
Therapie. 2019 Dec;74(6):557-567.
Pharmacoepidemiology.
Moore N, Blin P, Droz C.
Handb Exp Pharmacol. 2019;260:433-451.
Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study.
Villa A, Molimard M, Bignon E, Martinez B, Rouyer M, Mathoulin-Pelissier S, Baldi I, Verdun-Esquer C, Canal-Raffin M.
BMJ Open. 2019 Nov 10;9(11):e033040.
Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015): A cross-national drug utilization study.
Ibáñez L, Sabaté M1, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Heeke A, Huerta C, Martin Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjaer M, Andersen M, De Bruin ML, Groenwold R, van den Ham R, Souverein P, Klungel O, Gardarsdottir H.
Br J Clin Pharmacol. 2019 Nov;85(11):2524-2539.
Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France.
Bénard-Laribière A, Noize P, Girodet PO, Lassalle R, Dureau-Pournin C, Droz-Perroteau C, Fourrier-Réglat A, Salvo F, Bezin J, Pariente A; DRUGS-2M study group.
Therapie. 2019 Sep;74(4):469-476.
Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI.
Droz-Perroteau C, Blin P, Dureau-Pournin C, Thomas D, Danchin N, Tricoire J, Paillard F, Hercberg S, Guize L, Guiard E, Maïzi H, Bernard MA, Bénichou J, Moore N.
Therapie. 2019 Sep;74(4):459-468.
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, Lassalle R, Droz C, Moore N.
Stroke. 2019 Sep;50(9):2469-2476.
Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage
Langlade C, Gouverneur A, Bosco-Lévy P, Gouraud A, Pérault-Pochat MC, Béné J, Miremont-Salamé G, Pariente A, French Network of Pharmacovigilance Centres.
Br J Clin Pharmacol. 2019 Sep;85(9):2126-2133.
Bismuth Concentrations In Patients Treated In Real-Life Practice With A Bismuth Subcitrate-Metronidazole-Tetracyclin Preparation. The Saphary Study.
Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P.
Drug Saf. 2019 Aug;42(8):993-1003.
Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients.
Samalin E, Mazard T, Assenat E, Rouyer M, De la Fouchardière C, Guimbaud R, Smith D, Portales F, Ychou M, Fiess C, de Forges H, Lopez-Crapez E, Thézenas S.
Ann Oncol. 2019 Jul;30 Suppl 4:iv26-iv27.
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation.
Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455.
Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study.
Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A.
Am J Med. 2019 Jun;132(6):740-748.e7.
Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P, Gouverneur A, Langlade C, Miremont G, Pariente A.
Contraception. 2019 Jun;99(6):345-349.
A review of Algerian medicinal plants used in the treatment of diabetes.
Hamza N, Berke B, Umar A, Cheze C, Gin H, Moore N.
J Ethnopharmacol. 2019;238:111841.
Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
Gouverneur A, Bezin J, Jové J, Bosco-Lévy P, Fourrier-Réglat A, Noize P.
J Am Geriatr Soc. 2019 May;67(5):913-919.
Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE.
Drug Saf. 2019 Apr;42(4):559-572.
Pharmacoepidemiology of statins.
Bezin J, Moore N.
Therapie. 2019 Apr;74(2):261-269.
Pharmacoepidemiology of non-steroidal anti-inflammatory drugs.
Moore N, Duong M, Gulmez SE, Blin P, Droz C.
Therapie. 2019 Apr;74(2):271-277.
The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M.
Therapie. 2019 Apr;74(2):279-288.
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group.
Clin Colorectal Cancer. 2019 Mar;18(1):e150-e162.
Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.
Massin P, Creuzot-Garcher C, Kodjikian L, Girmens J.-F, Delcourt C, Fajnkuchen F, Glacet-Bernard A, Guillausseau P.-J, Ponthieux A, Blin P, Grelaud A.
Ophthalmic Res. 2019;62(2):101-110.
Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N.
Pharmacol Res. 2019 Mar;141:201-207.
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, Falissard B, Thomas-Delecourt F, Jové J, Lassalle R, Droz C, Moore N.
Atherosclerosis. 2019 Feb;281:98-106.
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
Br J Clin Pharmacol. 2019 Feb;85(2):432-441.
Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database.
Bosco-Lévy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, Blin P, Chatellier G, Looten V, Moore N.
Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):194-200.
Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria.
Opadeyi AO, Fourrier-Reglat A, Isah AO.
Ther Adv Drug Saf. 2019 Jan 25;10:2042098618816279.
2018
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.
Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.
Drug Saf. 2018 Nov;41(11):1049-1058.
Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study.
Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N.
Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1174-1181.
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK.
Lancet Psychiatry. 2018 Oct;5(10):824-835.
An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France.
Blin P, Demoly P, Drouet M, Falissard B, Lignot-Maleyran S, Maizi H, Lorrain S, Lassalle R, Droz-Perroteau C, Moore N, Molimard M.
Allergy Asthma Clin Immunol. 2018 Sep 24;14:38.
Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
Llorca PM, Bobes J, Fleischhacker WW, Heres S, Moore N, Bent-Ennakhil N, Sapin C, Loze JY, Nylander AG, Patel MX.
Eur Psychiatry. 2018 Aug;52:85-94.
Risk of Motor Vehicle Accidents Related to Sleepiness at the Wheel: A Systematic Review and Meta-Analysis.
Bioulac S, Micoulaud-Franchi JA, Arnaud M, Sagaspe P, Moore N, Salvo F, Philip P.
Sleep. 2018 Jul 1;41(7).
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group.
Clin Colorectal Cancer. 2018 Jun;17(2):129-139.
Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting.
Bezin J, Klungel OH, Lassalle R, Dureau-Pournin C, Moore N, Pariente A.
Clin Pharmacol Ther. 2018 Jun;103(6):1038-1046.
Assessment of the state of pharmacovigilance in the South-South zone of Nigeria using WHO pharmacovigilance indicators.
Opadeyi AO, Fourrier-Réglat A, Isah AO.
BMC Pharmacol Toxicol. 2018 May 31;19(1):27.
Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics.
Moore N, Scheiman JM.
Postgrad Med. 2018 Mar;130(2):188-199.
Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases.
Berdaï D, Thomas-Delecourt F, Szwarcensztein K, d'Andon A, Collignon C, Comet D, Déal C, Dervaux B, Gaudin AF, Lamarque-Garnier V, Lechat P, Marque S, Maugendre P, Méchin H, Moore N, Nachbaur G, Robain M, Roussel C, Tanti A, Thiessard F.
Therapie. 2018 Feb;73(1):1-12, 13-24.
Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
Gouverneur A, Salvo F, Berdaï D, Moore N, Fourrier-Réglat A, Noize P.
J Geriatr Oncol. 2018 Jan;9(1):15-23.
2017
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.
Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569.
Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.
Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Réglat A, Pariente A, Aparicio T, Miremont-Salamé G, Noize P.
Target Oncol. 2017 Dec;12(6):805-814.
National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.
Bosco-Lévy P, de Boissieu P, Gouverneur A, Noize P, Molimard M, Fourrier-Réglat A, Bezin J.
Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1233-1241.
Constituents and Antioxidant Activity of Bleeding Sap from Various Xinjiang Grapes.
Le L, Umar A, Iburaim A, Moore N.
Pharmacogn Mag. 2017 Oct;13(Suppl 3):S726-S730.
Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.
Blin P, Dureau-Pournin C, Lassalle R, Jové J, Thomas-Delecourt F, Droz-Perroteau C, Danchin N, Moore N.
Br J Clin Pharmacol. 2017 Sep;83(9):2056-2065.
A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU.
Weatherall M, Aantaa R, Conti G, Garratt C, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S.
Br J Clin Pharmacol. 2017 Sep;83(9):2066-2076.
False-positive results in pharmacoepidemiology and pharmacovigilance.
Bezin J, Bosco-Levy P, Pariente A.
Therapie. 2017 Sep;72(4):415-420.
Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study.
Blin P, Sevestre MA, Pouchain D, Gillet JL.
Thromb Res. 2017 Sep;157:117-119.
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.
Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N.
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962.
Agreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients.
Gouverneur A, Dolatkhani D, Rouyer M, Grelaud A, Francis F, Gilleron V, Fourrier-Réglat A, Noize P.
Rev Epidemiol Sante Publique. 2017 Aug;65(4):321-325.
Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France.
Bénard-Laribière A, Pariente A, Pambrun E, Bégaud B, Fardet L, Noize P.
BMJ Open. 2017 Jul 31;7(7):e015905.
Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study.
Née M, Avalos M, Luxcey A, Contrand B, Salmi LR, Fourrier-Réglat A, Gadegbeku B, Lagarde E, Orriols L.
PLoS Med. 2017 Jul 18;14(7):e1002347.
Methods for safety signal detection in healthcare databases: a literature review.
Arnaud M, Bégaud B, Thurin N, Moore N, Pariente A, Salvo F.
Expert Opin Drug Saf. 2017 Jun;16(6):721-732.
[Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)].
Philippe F, Blin P, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Velkovski-Rouyer M, Levy-Bachelot L, Steg G.
Ann Cardiol Angeiol (Paris). 2017 Apr;66(2):74-80.
Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RMC.
Clin Ther. 2017 Apr;39(4):759-770.
Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies.
Salvo F, Bezin J, Bosco-Levy P, Letinier L, Blin P, Pariente A, Moore N.
Pharmacol Res. 2017 Apr;118:43-52.
Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
Bezin J, Groenwold RH, Ali MS, Lassalle R, Robinson P, de Boer A, Moore N, Klungel OH, Pariente A.
Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):285-293.
Impact of a public media event on the use of statins in the French population.
Bezin J, Francis F, Nguyen NV, Robinson P, Blin P, Fourrier-Réglat A, Pariente A, Moore N.
Arch Cardiovasc Dis. 2017 Feb;110(2):91-98.
Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.
Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO.
Eur Respir J. 2017 Feb 15;49(2). pii: 1601794.
How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
Gouverneur A, Rouyer M, Grelaud A, Robinson P, Colombani F, Terrebonne E, Smith D, Fourrier-Réglat A, Noize P.
Fundam Clin Pharmacol. 2017 Feb;31(1):104-109.
Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study.
Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A.
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):162-169.
News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery.
Moore N, Hamza N, Berke B, Umar A.
Br J Clin Pharmacol. 2017 Jan;83(1):33-37.
2016
Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study.
Orriols L, Luxcey A, Contrand B, Gadegbeku B, Delorme B, Tricotel A, Moore N, Salmi LR, Lagarde E.
Br J Clin Pharmacol. 2016 Dec;82(6):1625-1635.
Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.
Théophile H, Moore N, Robinson P, Bégaud B, Pariente A.
Drug Saf. 2016 Dec;39(12):1197-1209.
Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
Bosco-Lévy P, Jové J, Robinson P, Moore N, Fourrier-Réglat A, Bezin J.
Br J Cancer. 2016 Oct 11;115(8):912-919.
Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study.
Ferland G, Feart C, Presse N, Lorrain S, Bazin F, Helmer C, Berr C, Annweiler C, Rouaud O, Dartigues JF, Fourrier-Reglat A, Barberger-Gateau P.
J Gerontol A Biol Sci Med Sci. 2016 Oct;71(10):1356-62.
Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis.
Blin P, Philippe F, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Leproust S, Levy-Bachelot L, Steg PG.
Int J Cardiol. 2016 Sep 15;219:387-93.
A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients.
Fiore M, Pillois X, Lorrain S, Bernard MA, Moore N, Sié P, Viallard JF, Nurden P.
Platelets. 2016 Sep;27(6):555-62.
Usage patterns of paracetamol in France.
Duong M, Gulmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.
Br J Clin Pharmacol. 2016 Aug;82(2):498-503.
Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.
Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A.
Eur J Clin Pharmacol. 2016 Jul;72(7):869-76.
Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction
Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung SC, Stogiannis D, Pujades-Rodriguez M, Timmis A, Denaxas SC, Danchin N, Stokes M, Thomas-Delecourt F, Emmas C, Hasvold P, Jennings E, Johansson S, Cohen DJ, Jernberg T, Moore N, Janzon M, Hemingway H.
Eur Heart J Qual Care Clin Outcomes. 2016 Jul 1;2(3):172-183.
Authors' reply to Tufan and colleagues and Boucaud-Maitre.
Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A.
BMJ. 2016 Jun 7;353:i3188.
Lessons from the fatal French study BIA-10-2474.
Moore N.
BMJ. 2016 May 18;353:i2727.
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A.
BMJ. 2016 May 3;353:i2231.
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Rouyer M, Fourrier-Réglat A, Smith D, Becouarn Y, Guimbaud R, Tubiana-Mathieu N, Robinson P, Jové J, Grelaud A, Noize P, Moore N, Ravaud A.
J Geriatr Oncol. 2016 May;7(3):187-94.
Does paracetamol still have a future in osteoarthritis?
Moore N, Salvo F, Duong M, Gulmez SE.
Lancet. 2016 May 21;387(10033):2065-2066.
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.
Eur J Cancer. 2016 Apr;57:31-8.
Bronchial Smooth Muscle Remodeling in Nonsevere Asthma.
Girodet PO, Allard B, Thumerel M, Begueret H, Dupin I, Ousova O, Lassalle R, Maurat E, Ozier A, Trian T, Marthan R, Berger P.
Am J Respir Crit Care Med. 2016 Mar 15;193(6):627-33.
A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.
Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.
Br J Clin Pharmacol. 2016 Mar;81(3):569-78.
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.
Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, Raschi E, Fourrier-Réglat A, Moore N, Sturkenboom M, Hazell On Behalf Of Investigators Of The Aritmo Consortium L; Investigators of the ARITMO Consortium.
Clin Pharmacol Ther. 2016 Mar;99(3):306-14.
A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.
Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, Begaud B, Tubert-Bitter P, Pariente A.
Drug Saf. 2016 Mar;39(3):251-60.
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
Grelaud A, Fourrier-Réglat A, Fitoussi O, Facon T, Jové J, Bénichou J, Robinson P, Marit G, Rouyer M, Moore N, Noize P; VESUVE Study Group.
Leuk Lymphoma. 2016;57(6):1349-54.
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jove J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group.
Target Oncol. 2016 Feb;11(1):83-92.
Big data" and "open data": What kind of access should researchers enjoy?"
Chatellier G, Varlet V, Blachier-Poisson C; participants of Giens XXXI, Round Table No. 6.
Therapie. 2016 Feb;71(1):97-105, 107-14.
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, Perina L, Hazell L, Moretti U, Sturkenboom M, Garbe E, Pariente A, De Ponti F.
Drug Saf. 2016 Jan;39(1):59-68.
2015
Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database.
Bezin J, Girodet PO, Rambelomanana S, Touya M, Ferreira P, Gilleron V, Robinson P, Moore N, Pariente A.
Fundam Clin Pharmacol. 2015 Dec;29(6):586-91.
A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU.
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S.
Intensive Care Med Exp. 2015 Dec; 3(Suppl 1): A322.
Incidence of Cardiovascular Events Following Myocardial Infarction in France: an Observational Analysis Using a Claims Database.
Philippe F, Blin P, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG.
Value Health. 2015 Nov;18(7):A382.
Increased Costs Due To Myocardial Infarction (Mi) In France: An Observational Analysis Using A Claims Database.
Blin P, Philippe F, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG.
Value Health. 2015 Nov;18(7):A386.
Benefit-Risk of Vka for Atrial Fibrillation Before Doac: a Cohort Study in a Claims and Hospitalization Database.
Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.
Value Health. 2015 Nov;18(7):A381.
Methodological Considerations for the Implementation of A European Mandated Retrospective Drug Utilisation Study (Dus) to Investigate the Use of Dexmedetomidine (Dexdor®) in Clinical Practice.
Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S.
Value Health. 2015 Nov;18(7):A723.
Drug use in French children: a population-based study.
Bénard-Laribière A, Jové J, Lassalle R, Robinson P, Droz-Perroteau C, Noize P.
Arch Dis Child. 2015 Oct;100(10):960-5.
Liver transplant associated with paracetamol overdose: results from the seven-country SALT study.
Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Moore N.
Br J Clin Pharmacol. 2015 Sep;80(3):599-606.
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F.
Br J Clin Pharmacol. 2015 Aug;80(2):285-93.
Antihypertensive drugs, hypotension, and ischemic colitis.
Blin P.
Am J Cardiovasc Drugs. 2015 Apr;15(2):77-9.
Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database.
Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jové J, Lassalle R, Robinson P, Poutignat N, Droz-Perroteau C, Moore N.
Eur J Neurol. 2015 Mar;22(3):464-71.
Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).
Jacquet A, Grolleau A, Jove J, Lassalle R, Moore N.
J Int Med Res. 2015 Feb;43(1):54-66.
2014
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
Fourrier-Reglat A, Smith D, Rouyer M, Benichou J, Guimbaud R, Becouarn Y, Bernard O, Noize P, Moore N, Ravaud A; ETNA study group.
Target Oncol. 2014 Dec;9(4):311-9.
Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database.
Sabouret P, Depret-Bixio L, Cotte FE, Marie P, Bedira N, Blin P.
Clin Res Cardiol. 2014 Nov;103(11):887-93.
Scoring of medical publications with SIGAPS software: Application to orthopedics.
Rouvillain JL, Derancourt C, Moore N, Devos P.
Orthop Traumatol Surg Res. 2014 Nov;100(7):821-5.
Encepp-HTA Working Group Survey on Capacity To Conduct Research in Support Of Health Technology Assessment.
Toussi M, Lis Y, Qizilbash N, Blake KV, Ehrenstein V, Kurz X, Moore N, Sinclair M.
Value Health. 2014 Nov;17(7):A440.
The 3.5-Year Mortality Impact Of Drugs In Secondary Prevention Of Myocardial Infarction In Real-Life (Interim Analysis Of The Eole Cohort).
Droz C, Dureau C, Thomas D, Danchin N, Tricoire J, Benichou J, Paillard F, Hercberg S, Sibon I, Rouanet F, Rambelomanana S, Maizi H, Bernard MA, Blin P, Moore N.
Value Health. 2014 Nov;17(7):A476.
Type 2 Diabetes Treatment Patterns Across Europe.
Heintjes E, Overbeek JA, Blin P, Hall GC, Lapi F, Prieto AD, Bezemer ID.
Value Health. 2014 Nov;17(7):A359.
Misuse, Abuse, and Diversion of Instanyl® (Fentanyl Nasal Spray) in France.
Blin P, Dureau C, Lamarque S, Bernard MA, Robinson P, Lassalle R, Grolleau A, Droz C, Moore N.
Value Health. 2014 Nov;17(7):A649.
Long-term chronic diseases and crash responsibility: a record linkage study.
Orriols L, Avalos-Fernandez M, Moore N, Philip P, Delorme B, Laumon B, Gadegbeku B, Salmi LR, Lagarde E.
Accid Anal Prev. 2014 Oct;71:137-43.
SIGAPS: A software package for the evaluation of medical publications.
Derancourt C, Devos P, Moore N, Rouvillain JL.
Ann Dermatol Venereol. 2014 Aug-Sep;141(8-9):531-5.
New oral anticoagulants (NOAC) and liver injury.
Moore N, Blin P, Gulmez SE.
J Hepatol. 2014 Aug;61(2):198-9.
Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database.
Geniaux H, Assaf D, Miremont-Salame G, Raspaud B, Gouverneur A, Robinson P, Pariente A, Salvo F.
Drug Saf. 2014 Jul;37(7):537-42.
Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.
Duong M, Salvo F, Pariente A, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.
Br J Clin Pharmacol. 2014 May;77(5):887-95.
Fibrates and risk of cancer in tissues with high PPAR-alpha concentration: a nested case-control study.
Salvo F, Bazin F, Kostrzewa A, Bandre C, Robinson P, Moore N, Begaud B, Pariente A.
Drug Saf. 2014 May;37(5):361-8.
Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies.
Salvo F, Antoniazzi S, Duong M, Molimard M, Bazin F, Fourrier-Réglat A, Pariente A, Moore N.
Expert Opin Drug Saf. 2014 May;13(5):573-85.
Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, Moore N, Droz-Perroteau C, Fourrier-Reglat A.
Eur J Clin Pharmacol. 2014 Apr;70(4):429-36.
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
Fourrier-Reglat A, Noize P, Facon T, Fermand JP, Fitoussi O, Marit G, Thomare P, Robinson P, Bignon E, Jove J, Lassalle R, Rouyer M, Grelaud A, Moore N; VESUVE study group.
Leuk Lymphoma. 2014 Apr;55(4):848-54.
Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial.
Philip P, Chaufton C, Taillard J, Capelli A, Coste O, Leger D, Moore N, Sagaspe P.
Sleep. 2014 Mar 1;37(3):483-7.
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.
Moore N, Salvo F, Duong M, Blin P, Pariente A.
Expert Opin Drug Saf. 2014 Feb;13(2):167-79.
Continuation rates of levetiracetam in children from the EULEVp cohort study.
Dureau-Pournin C; Pedespan, JM; Droz-Perroteau, C; Lavernhe, G; Mann M, Pollet C, Robinson P, Jove J, Moore N, Fourrier-Reglat A; EULEV study group.
Eur J Paediatr Neurol. 2014 Jan;18(1):19-24.
2013
Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S, Schuld P, Belanger C, Mahon FX, Molimard M.
Fundam Clin Pharmacol. 2013 Dec;27(6):690-7.
Relative risks from case-population data.
Moore N, Gulmez SE, Blin P, Lassalle R, Jove J, Théophile H, Bégaud B, Larrey D, Bénichou J.
Epidemiology. 2013 Nov;24(6):935-6.
Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from the Study of Acute Liver Transplant (SALT).
Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D.
Drug Saf. 2013 Sep;36(9):757-64.
Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre, Sapède C, Moore N; participants of round table N° 5 of Giens Workshops XXVIII (th), Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C.
Therapie. 2013 Jul-Aug;68(4):241-52.
Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France
Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d’Ortho M-P, Launois S, Lignot S, Bourgin P, Nogues B, Rey M, Bayard S, Scholz S, Lavault S, Tubert-Bitter P, Saussier C, Pariente A.
Brain. 2013 Aug;136(Pt 8):2486-96.
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.
Léauté-Labrèze C, Dumas de la Roque E, Nacka F, Abouelfath A, Grenier N, Rebola M, Ezzedine K, Moore N.
Br J Dermatol. 2013 Jul;169(1):181-3.
Observation of the long-term effects of lifestyle intervention during balneotherapy in metabolic syndrome.
Gin H, Demeaux JL, Grelaud A, Grolleau A, Droz-Perroteau C, Robinson P, Lassalle R, Abouelfath A, Boisseau M, Toussaint C, Moore N.
Therapie. 2013 May-Jun;68(3):163-7.
The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.
Moore N.
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:33-41.
Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries.
Clay E, Falissard B, Moore N, Toumi M.
Eur J Clin Pharmacol. 2013 Apr;69(4):1-10.
Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.
Guelfucci F, Clay E, Aballéa S, Lassalle R, Moore N, Toumi M.
BMC Endocr Disord. 2013 Apr 29;13:15.
Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N.
Drug Saf. 2013 Apr;36(4):217-30.
Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT).
Gulmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, de Vries C, Sturkenboom M, Perez-Gutthann S, Bénichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N.
Eur J Clin Pharmacol. 2013 Mar;69(3):605-16.
Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study.
Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N.
Drug Saf. 2013 Feb;36(2):135-44.
Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France.
Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B.
Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):160-7.
Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.
Smith D, Terrebonne E, Rouyer M, Blanc JF, Breilh D, Pedeboscq S, Le Monies A, Lecomte C, Lassalle R, Moore N, Fourrier-Réglat A.
Fundam Clin Pharmacol. 2013 Feb;27(1):113-9.
2012
One-year effectiveness of a 3-week balneotherapy program for the treatment of overweight or obesity.
Hanh T, Serog P, Fauconnier J, Batailler P, Mercier F, Roques CF, Blin P.
Evid Based Complement Alternat Med. 2012;2012:150839.
Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users.
Droz-Perroteau C, Marchal C, Dureau-Pournin C, Lassalle R, Jové J, Robinson P, Lavernhe G, Vespignani H, Moore N, Fourrier-Réglat A; Eulev Study Group.
Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1183-9.
Administrative complexities for a European observational study despite directives harmonising requirements.
Gülmez SE, Lignot-Maleyran S, de Vries CS, Sturkenboom M, Micon S, Hamoud F, Blin P, Moore N.
Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):851-6.
Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions.
Gueyffier F, Strang CB, Berdeaux G, França LR, Blin P, Massol J; participants of Round Table N°6 of Giens XXVII.
Therapie. 2012 Jul-Aug;67(4):359-66, 367-74.
Preventive and curative effect of Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet.
Hamza N, Berke B, Cheze C, Le Garrec R, Umar A, Agli AN, Lassalle R, Jové J, Gin H, Moore N.
J Ethnopharmacol. 2012 Jul 13;142(2):516-22.
Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis.
Bernard MA, Bénichou J, Blin P, Weill A, Bégaud B, Abouelfath A, Moore N, Fourrier-Réglat A; CADEUS Team.
Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):573-83.
[Who are patients suffering from bipolar disorders in France? The TEMPPO survey: patients' sociodemographic and clinical characteristics data].
de Carvalho W, Nuss P, Blin P, Arnaud R, Filipovics A, Loze JY, Dillenschneider A.
Encephale. 2012 Jun;38(3):211-23.
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N.
Diabetologia. 2012 Mar;55(3):644-53.
[Treatment practices in the management of patients with bipolar disorder in France. The TEMPPO study].
Nuss P, de Carvalho W, Blin P, Arnaud R, Filipovics A, Loze JY, Dillenschneider A.
Encephale. 2012 Feb;38(1):75-85.
2011
Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.
Gulmez SE, Droz-Perroteau C, Lassalle R, Blin P, Bégaud B, Rossignol M, Moore N, Fourrier-Réglat A; CADEUS study group.
Eur J Clin Pharmacol. 2011 Aug;67(8):833-8.
How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M, Moore N, Lechat P; participants of Round Table N° 3 of Giens XXVI.
Therapie. 2011 Jul-Aug;66(4):331-4, 327-30.
Journal’s withdrawal of article. Paper OK, title wrong.
Moore N.
BMJ. 2011 May 10;342:d2732.
The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year.
Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A; EULEV Study Group.
Br J Clin Pharmacol. 2011 Jan;71(1):121-7.
Treatment of high fat diet induced type 2 diabetes in C57BL/6J mice by two medicinal plants used in traditional treatment of diabetes in the east of Algeria.
Hamza N, Berke B, Cheze C, Le Garrec R, Lassalle R, Agli AN, Robinson P, Gin H, Moore N.
J Ethnopharmacol. 2011 Jan 27;133(2):931-3.
2010
Effectiveness of antibiotics for acute sinusitis in real-life medical practice.
Blin P, Blazejewski S, Lignot S, Lassalle R, Bernard MA, Jayles D, Théophile H, Bénichou J, Demeaux JL, Ebbo D, Franck J, Moride Y, Peyramond D, Rouveix B, Sturkenboom M, Gehanno P, Droz C, Moore N.
Br J Clin Pharmacol. 2010 Sep;70(3):418-28.
Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE study.
Saraux A, Combe B, Blin P, Bregman B, Chartier M, Durieux-Mehlman S, Guillemin F.
Clin Exp Rheumatol. 2010 May-Jun;28(3):325-32.
Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort.
Fourrier-Réglat A, Cuong HM, Lassalle R, Depont F, Robinson P, Droz-Perroteau C, Pariente A, Bégaud B, Blin P, Moore N.
Pharmacoepidemiol Drug Saf. 2010 May;19(5):474-81.
Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.
Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N.
Br J Clin Pharmacol. 2010 Mar;69(3):295-302.
Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in France.
Depont F, Hunsche E, Abouelfath A, Diatta T, Addra I, Grelaud A, Lagnaoui R, Molimard M, Moore N.
Fundam Clin Pharmacol. 2010 Feb;24(1):101-8.
Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation.
Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, Garrigue I, Hawchar O, Siberchicot F, Moore N, Moreau JF, Dechanet-Merville J, Merville P.
J Am Soc Nephrol. 2010 Jan;21(1):181-8.
2009
No obvious extra cardiovascular risk associated with low-dose NSAIDs.
Moore N.
Clin Pharmacol Ther. 2009 Dec;86(6):600-1; author reply 602-4.
The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
Blazejewski S, Georges A, Forest K, Corcuff JB, Abouelfath A, Girodet PO, Kamagate M, Jacquet A, Pillet O, Bordenave L, Moore N.
Fundam Clin Pharmacol. 2009 Jun;23(3):339-44.
Homoeopathic product licence. Being useless may be useful.
Moore N.
BMJ. 2009 Jun 9;338:b2334.
The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers.
Rossignol M, Abouelfath A, Lassalle R, Merlière Y, Droz C, Bégaud B, Depont F, Moride Y, Blin P, Moore N, Fourrier-Réglat A.
Br J Clin Pharmacol. 2009 Jan;67(1):118-24.
2008
Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation.
Molimard M, Girodet PO, Pollet C, Fourrier-Réglat A, Daveluy A, Haramburu F, Fayon M, Tabarin A.
Drug Saf. 2008;31(9):769-74.
Impact of prescriber nonresponse on patient representativeness.
Fourrier-Réglat A, Droz-Perroteau C, Bénichou J, Depont F, Amouretti M, Bégaud B, Moride Y, Blin P, Moore N; CADEUS Team.
Epidemiology. 2008 Mar;19(2):186-90.
2007
Drug-drug interactions with systemic antifungals in clinical practice.
Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galpérine T, Abouelfath A, Valentino R, Dupon M, Hébert G, Moore N.
Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1227-33.
Assessment of the handling of inhaler devices: an observational study of children in primary care.
Malot L, Molimard M, Abouelfatah A, Lignot S, Depont F, Moore N, Fayon M.
Arch Pediatr. 2007 Oct;14(10):1190-5.
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N; CADEUS Team.
Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):891-900.
Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey.
Diatta T, Blazejewski S, Portier A, Lignot S, Quesnot A, Moore N, Fourrier-Réglat A.
Fundam Clin Pharmacol. 2007 Aug;21(4):371-8.
The CADEUS study: methods and logistics.
Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Blin P, Moore N; CADEUS Team.
Pharmacoepidemiol Drug Saf. 2007 May;16(5):571-80.
Integrity of scientific data: transparency of clinical trial data.
Moore N, Juillet Y, Bertoye PH; Round Table No 4, Giens XXII.
Therapie. 2007 May-Jun;62(3):203-9, 211-6.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX.
Blood. 2007 Apr 15;109(8):3496-9.
Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.
Moore N.
Clin Drug Investig. 2007;27(3):163-95.
Ibuprofen: a journey from prescription to over-the-counter use.
Moore N.
J R Soc Med. 2007;100 Suppl 48:2-6.
235 total publications, 70 publications last 5 years.